NCT04293393 2026-03-12
CARABELA
Spanish Breast Cancer Research Group
Phase 2 Active not recruiting
Clinical Trials
10 trialsNCT03879577 2026-01-21
Assessing the Response Rate of Neo-adjuvant Taxotere and Trastuzumab in Nigerian Women With Breast Cancer
University of Chicago
Phase 2 Active not recruiting
NCT06001762 2026-01-16
TRADE: Dose Escalation Tolerability of Abemaciclib in HR+ HER2- Early Stage Breast Cancer
Dana-Farber Cancer Institute
Phase 2 Active not recruiting
NCT07127315 2025-08-17
Assessing Gonadotropin-Releasing Hormone Agonists Benefit in Preserving the Ovarian Function in Premenopausal Breast Cancer Patients During Chemotherapy
Helwan University
Completed
NCT05720260 2024-06-10
Immunotherapy, Hormone Therapy, and AKT Inhibitor for Premenopausal ER Positive MBC
National Taiwan University Hospital
Phase 2 Recruiting
NCT06346457 2024-04-04
Breast Cancer & Antiestrogenic Therapy & Brain
International Research Training Group 2804
Not yet recruiting
NCT05891093 2024-02-08
Efficacy and Safety of Fluzoparib Combined With Adjuvant Endocrine Therapy for HR+/HER2- SNF3-subtype Early Breast Cancer (BCTOP-L-A01)
Fudan University
Phase 3 Recruiting
NCT05638594 2023-03-20
Pyrotinib Combined With Trastuzumab, Dalpiciclib, Letrozole Versus TCbHP (Trastuzumab Plus Pertuzumab With Docetaxel and Carboplatin) as Neoadjuvant Treatment in HR +/HER2 + Breast Cancer
Shengjing Hospital
Phase 2 Recruiting
NCT02592746 2019-04-08
A Study of Palbociclib With Exemestane Plus GnRH Versus Capecitabine in Premenopausal Women With HR+ MBC
Samsung Medical Center
Phase 2 Unknown
NCT02483767 2017-10-17
POF
Peking Union Medical College Hospital
Phase 3 Completed